EXPEDEON

Creating and Commercializing Innovation in Life Sciences

May 15, 2019

1

Disclaimer

This document is intended for prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the development phase. This document also may contain projections and/or estimates about and descriptions of plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements. These statements are forward-looking and are subject to risks and uncertainties, many of which are beyond our control and are not to be regarded as guarantees of future events.

Actual results could differ materially depending on a number of factors, including the timing and effects of regulatory actions, the results of product tests, the Company's relative success developing and gaining market acceptance for any new products, and the effectiveness of patent protection.

There can be no guarantee regarding the results of the product tests or other on going studies with our products. There can be no guarantee that our products in development will be approved for marketing in a timely manner, if at all.

The Company disclaims any intent or obligation to update these forward-looking statements or the factors that may affect the Company's future results, performance or achievements, even if new information becomes available in the future.

2

3

Expedeon Overview

• Creating and commercializing Innovation in Life Sciences

• high value-add products for research use

• integrating our products/technologies into third-party diagnostic solutions

• Based on proprietary technology and patents

• Operational headquarters in Cambridge, UK; local operations in the US, Australia, Spain & Germany

• 110 staff working across R&D, manufacturing, sales and G&A

• strong year by year revenue growth

• increasing profitability

4

Corporate Vision

• Become a market leading innovator enabling advances in

• oncology and immunology research

• clinical diagnostics

• therapeutics solutions

• By developing products and services built on proprietary technology, which:

• accelerate and simplify research

• enhance diagnostic and therapeutic products development

5

2019 Objectives

• Continue to grow revenue and profitability

• focus on organic

• strategic M&A possible

• Continue investment in developing technologies and products

• Focus group activity around leading market trends:

• onco-immunology

• liquid Biopsy

• multi-omics

• multi-plexing

6

Expedeon Technology Value Drivers

Technology Value

Drivers

Lightning Link®

CaptsureTM

Colloidal Gold

Trueprime®Sunscript®

RunBlue®

InstantBlueTM

Driven by Innovation:

• strong portfolio and pipeline of innovative and

disruptive products

• patent portfolio across broad market segments

• technology portfolio fits market trends toward

multiplex and multiomics

7

‘MultiOmics’Approach:NewMarketStandard

OncoImmuneDrug

Development

Targeted Genomics

(DNA)

Transcriptomics (mRNA)

Proteomics (Protein)

Market Trends in OncoImmune Research:

• multiple datasets from single sample

• single cell resolution

• direct tissue imaging

• quantitative analysis

8

Drive towards Higher Plex Solutions

Multitarget Antibody Barcoding

Bead based

Isotopic metals

DNA oligos

Fluorometric

Plate Based

Customer needs

• Fast and reliable barcoding

• Working at small scale

• Cross platform applicability

Expedeon Solutions

• LightningLink®

• CaptsureTM

9

TruePrime: New Application Areas

TruePrime

WGALiquid Biopsy

Single Cell

Gene Therapy

Homogenous Assays

• Potential treatment for a wide range of

conditions: cancer, cystic fibrosis, heart

disease, diabetes, hemophilia, AIDS,…

• DNA as therapeutic agent

• Various delivery systems to get DNA into

patient cells

• DNA retail price: €300,000/g

• Therapy costs: >$M per patient

• Homogenous = no wash

• Amplified DNA = readout

• Increased sensitivity

• Multiplex

• HTS

• RUO & Clinical potential

10

Development Stages➢ Concept: Identify customer “pain points”

(slow, repetitive and costly processes)

➢ Design: Conceptually scope solution(focussed on speed, ease of use, cost)

➢ Develop: R&D project

➢ Commercialise: Test prototype through iterative process with partners(prospective customers product test)

➢Manufacture: Upscale production quality and scale; establish price points and margin

➢Sell: Product Launch

11

Development PipelineIndicative incremental revenue opportunities: (indicative revenue potential by 2022 alongside existing product revenues)

Important Notice:

This table presents indicative revenueopportunities relating to commercialprojects in which Expedeon group is en-gaged. These projects are all subject tocommercial risk including competitoractivity, competing intellectual propertyand cost considerations. It is possible thatnone of these projects are successfullyconcluded.

Growth Opportunity# active

opportunities

revenue opportunity €'million

Gene Therapy 2 € 10.0

Oligo barcoding 7 € 5.0

Isotope barcoding 3 € 5.0

Multiplex 3 € 3.0

Dx supplies 9 € 7.0

24 € 30.0

12

2018 Corporate Milestones

UK company integration

Name change to Expedeon

Acquisition of TGR Biosciences

2View product launch

Significant commercial transactions

• A leading antibody supplier

• Quanterix

13

2018 Numbers

2018 Performance

• Revenue €13.1

• EBITDA (adjusted) €1.0

• Net Result -€0.3

• Operating Cashflow -€0.2-6

-4

-2

0

2

4

6

8

10

12

14

Revenue EBITDA Net Loss Oper CF

Mill

ion

eu

ro

2016 2017 2018

14

Financial Objectives 2019

Continue to strengthen product portfolio

Drive organic revenue from product sales and licensing

Potentially add complementary acquisition

Outlook on 2019 financial objectives

• Revenues: double digit revenue growth

• EBITDA: adjusted EBITDA EUR >2 million

The goal of the Company is to achieve a strong flow of revenues with sector conventional profitability margins.

15

Take Aways

• Strongest ever financial year and position for Expedeon

• Strategy has brought company stability and independence

• Expedeon now a strong platform to exploit exciting opportunities

• R&D capabilities to continue driving double-digit growth

• Exciting product developments which herald another step change for the company

16

Thank You for Your Attention

For more information, please contact:

www.expedeon.com

www.investors.expedeon.com

Dr. Heikki Lanckriet, CEO/CSO

Email: heikki.lanckriet@expedeon.com

Phone: +44 1223 873364

Raimund Gabriel

Email: expedeon@mc-services.eu

Phone: +49 89 210 228 0

MC Services AG

Expedeon AG